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Telmisartan shows an equivalent effect of vitamin C in further improving endothelial 
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Background: Long-lasting hyperglycemia in type 1 diabetic patients induces permanent alterations 
of endothelial function, by increased oxidative stress, even when glycemia is normalized.  
Methods and Results: In this study 36 type 1 diabetic patients and 12 controls were enrolled. The 
diabetic patients were divided in three groups. The first group was treated for 24h with insulin, 
achieving a near-normalization of glycemia. At the 12 h of this treatment vitamin C  was added for 
the remaining 12h.The second group was treated for 24h with vitamin C. At the 12 h of this 
treatment insulin was started, achieving a near-normalization of glycemia for the remaining12h.The 
third group was treated for 24h with both vitamin C and insulin, achieving near normalization of 
glycemia. The same protocols were run after 1 month of Telmisartan or placebo. Neither 
normalization of glycemia or vitamin C treatment alone was able to normalize endothelial 
dysfunction or oxidative stress. Combining insulin and vitamin C normalized endothelial 
dysfunction and decreased oxidative stress to normal level. Telmisartan significantly improved 
basal endothelial function and decreased nitrotyrosine plasma levels. In patients treated with 
Telmisartan a near normalization of both flow mediated vasodilation and oxidative stress was 
achieved when glycemia was normalized, while adding vitamin C infusion did not show further 
effect on endothelial function or nitrotyrosine plasma levels.  
Conclusions: These data indicate that combining the normalization of glycemia with an antioxidant 
can normalize endothelial function in type 1 diabetic patients and that Telmisartan works as 
antioxidant as vitamin C. 
  2INTRODUCTION 
An increased incidence of macrovascular 
diseases in type 1 diabetes has long been 
recognized (1).The accelerated macrovascular 
disease is due partly to the increased incidence 
of classical risk factors, such as hypertension 
and dyslipidemia (2). However, recent 
evidence suggests that hyperglycemia also 
plays a significant role (3). 
The endothelium is a major organ involved in 
the development of cardiovascular disease even 
in diabetes, and the presence of an endothelial 
dysfunction has often been reported in diabetes 
and been found as independent predictor of a 
future cardiovascular disease (4).  
Several studies have shown that hyperglycemia 
induces an endothelial dysfunction in both 
diabetic and non-diabetic subjects (5-7), 
however, in type 1 diabetic patients endothelial 
dysfunction has been reported to present even 
when normoglycemia is achieved (8-9). 
Evidences indicate that hyperglycemia induces 
endothelial dysfunction through the generation 
of oxidative stress (for review see 10), which 
has been suggested to be the key player in the 
generation of the diabetic complications, both 
micro and macrovascular (11). We have 
recently demonstrated that a near normalization 
of endothelial dysfunction can be achieved in 
type 1 diabetic patients combining an optimal 
control of glycemia with the infusion of the 
antioxidant vitamin C (12). Several compounds 
already in the clinical practice have the 
property of reducing oxidative stress generation 
(10). In particular, the AT-1 receptor blockers 
have been shown to be effective (13-14). 
In this study we have evaluated the impact of 
the treatment with telmisartan, alone or in 
combination with normalization of glycemia, 
on the endothelial function and oxidative stress 
in type 1 diabetic patients. Furthermore, the 
effect of adding vitamin C has also been 
evaluated.  
 
RESEARCH DESIGN AND METHODS 
Subjects:  Experiments were performed in 36 
type 1 diabetic patients. 12 age and BMI 
matched healthy volunteers served as control 
group (Table 1).  
The diabetic subjects were divided in three 
subgroups, matched for sex, age, BMI, 
metabolic control and duration of the disease 
(Table 1). None of the selected patients was 
hypertensive, microalbuminuric or on drug 
treatment, excluding insulin. Lipid levels were 
also normal. 
The study was approved by the Local Ethical 
Committee and all subjects gave written 
informed consent. 
 
Protocol: First Phase 
All experiments were performed in a quiet, 
temperature-controlled room (24–25°C) after 
an overnight fast. Subjects were not allowed to 
smoke, drink (except for water), or eat for at 
least 10 h before the experiment. They were 
studied in the supine position and remained in 
bed during the experiments. On the morning of 
the experiments, the diabetic patients omitted 
their insulin injection.  
In the diabetic patients, a catheter was inserted 
into an antecubital vein for the infusion of one 
of the three treatments described below. 
The treatments consisted in: 
A: insulin (Actrapid, Novo Nordisk, 
Bagsvaerd, Denmark) and/or 5% glucose to 
keep blood glucose levels between 4 and 6 
mmol/l for 24 hours. The amount of insulin 
infused was based on the individual daily 
insulin dose. Blood glucose levels were 
determined every 5 min with adjustment of the 
intravenous insulin infusion, until steady-state 
glucose levels were between 4 and 6 mmol/l. 
At the steady state, venous glucose samples 
were drawn every 30 min. After 12 hours, 
vitamin C infusion, at the rate of 3 mg/min 
(15), was also started and continued for the 
remaining 12 hours; 
B: vitamin C, at the rate of 3 mg/min (15), for 
24 hours. After 12 hours, insulin and/ or 5% 
glucose infusion, aiming to maintain blood 
glucose levels between 4 and 6 mmol/l, as 
described above, for the remaining 12 hours; 
C: insulin and/or 5% glucose to keep blood 
glucose levels between 4 and 6 mmol/l plus   
vitamin C infusion, at the rate of 3 mg/min 
(15), for 24 hours.  
 
 
  3Second Phase: Telmisartan treatment 
After the first phase of the study, Telmisartan 
(40 mg /day, six patients of each group) or 
placebo (six patients of each group) treatment 
was started for 1 month. 
At the end of the treatment period, the 
protocols above described were repeated. 
 
In all the experiments, of the first and the 
second phase, at baseline and after 12 and 24 
hours, glycemia, endothelial function (flow 
mediated dilatation: FMD) and nitrotyrosine 
plasma level were evaluated. 
 
Biochemical Measurements. Cholesterol and 
triglycerides were measured enzymatically 
(Roche Diagnostics, Basel, Switzerland). HDL-
C was estimated after precipitation of 
apolipoprotein B with 
phosphotungstate/magnesium (16). LDL-C was 
calculated after lipoprotein separation (17). 
Plasma glucose was measured by the glucose-
oxidase method, HbA1c by HPLC. 
 
Nitrotyrosine. 
Nitrotyrosine plasma concentration was 
assayed by enzyme-linked immunosorbent
 
assay (ELISA), as previously described (18).
 
 
Endothelial Function.   
Endothelial function was evaluated measuring 
the flow-mediated vasodilation (FMD) of the 
brachial artery as previously reported. (19). At 
the end of each test, the subjects lay quietly for 
15 min. Then, sublingual nitroglycerin (0.3 mg) 
was administered and 3 min later the last 
measurements were performed. Response to 
nitroglycerin was used as a measure of 
endothelium-independent vasodilation. All 
studies were performed in a quiet and 
temperature-controlled room (22° C to 23° C). 
 
Statistical Analysis. As in previous studies (6, 
20) The Kolmogorov-Smirnov algorithm was 
used to determine whether
 each variable had a 
normal distribution. Comparisons of baseline 
data among the groups
 were performed by use 
of unpaired Student’s t test. Paired
 Student’s t 
test was used to compare the various 
parameters
  before and after each treatment. 
Changes in variables during
  the tests were 
assessed by 2-way ANOVA with repeated 
measures.
  If differences reached statistical 
significance, post hoc analyses
 with a 2-tailed 
paired t test was used to assess differences
 at 
individual time periods in the study, with 
Bonferroni’s
  correction for multiple 
comparisons. Statistical significance
  was 
defined as P<0.05. 
 
RESULTS 
Phase 1: Baseline nitrotyrosine was increased 
in diabetic patients, while FMD was reduced 
(table I). 
As previously reported (12), in the treatment A 
and C, glycemia was almost normalized after 
12 and 24 hours (p< 0.001 vs baseline; figure 1 
and 3), while in the treatment B glycemia was 
normal at 24 h (p< 0.001 vs baseline; figure 2). 
After 12 hours nitrotyrosine plasma levels 
significantly decreased in all the treatments (p< 
0.01 vs baseline; figure 1, 2 and 3): more 
significantly in the treatment C compared to the 
two others (p< 0.01 vs A and p<0.05 vs B, 
respectively), and more in the treatment B 
compared to A (p<0.05). At 12 h, FMD 
increased (p< 0.01 vs baseline; figure 1, 2 and 
3): again more significantly in the treatment C 
compared to the two others (p< 0.01 vs A and 
p<0.05 vs B, respectively), and more in the 
treatment B compared to A (p<0.05).  
After 24 hours, the plasma levels of 
nitrotyrosine were significantly decreased 
compared to the levels of 12 h in the treatment 
A and B (p<0.01), but not in C. After 24 hours 
there were no differences between the plasma 
levels of nitrotyrosine reached in each of the 
three treatments. 
FMD was significantly increased compared to 
the levels of 12 h in the treatment A and B 
(p<0.01), but not in C. After 24 hours also for 
FMD there were no differences between the 
three treatments. 
Endothelium-independent vasodilation did not 
change during any of the tests (data not 
shown). 
 
Second Phase: Telmisartan treatment. 
One month of treatment with Telmisartan 
significantly improved baseline FMD and 
reduced nitrotyrosine plasma levels (Table 2). 
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normalized after 12 h also FMD was almost 
normalized (p<0.01 vs baseline, p<0.05 vs 
placebo, figure 1), while nitrotyrosine was 
significantly reduced (p<0.01 vs baseline, 
p<0.05 vs placebo, figure 1), in the group 
treated with Telmisartan. Adding vitamin C did 
not change the results. 
Similarly, in the protocol B, the infusion of 
vitamin C had not impact on both FMD and 
nitrotyrosine plasma level, while the 
normalization of glycemia at 24 h normalized 
FMD (p<0.01 vs baseline, p<0.05 vs placebo, 
figure 2), and reduced nitrotyrosine plasma 
levels (p<0.01 vs baseline, p<0.05 vs placebo, 
figure 2). 
In the protocol C, the normalization of FMD 
(p<0.01 vs baseline, p<0.05 vs placebo at both 
12 and 24 h, figure 3), and the reduction of 
nitrotyrosine plasma levels (p<0.01 vs baseline, 
p<0.05 vs placebo at both 12 and 24 h, figure 
3), were achieved after 12 h and persisted until 
the 24 h. 
 
Any variation of the endothelial independent 
vasodilation was found during the all the 
experiments. 
 
DISCUSSION 
This study confirms that in type 1 diabetic 
patients only the simultaneous normalization of 
glycemia and the use of an antioxidant, such as 
vitamin C, can normalize endothelial 
dysfunction (12). At the same time, the 
possibility of improving endothelial function in 
type 1 diabetes, as already reported for type 2 
diabetic patients, using an AT-1 receptor 
blocker, in this case Telmisartan, is also 
reported (20). However, for the first time, we 
are able to show that Telmisartan in 
combination with the normalization of 
glycemia may lead to the almost normalization 
of the endothelial function. Furthermore, it is 
also shown that adding vitamin C does not 
influence the effect of the treatment with 
Telmisartan. 
The role of oxidative stress in this phenomenon 
appears crucial: in the phase 1 of the study, 
when endothelial function is still altered after 
12 h of normalization of glycemia or 12 h 
vitamin C treatment, nitrotyrosine, a good 
marker of peroxynitrite and nitrosative stress, is 
still increased, while when endothelial function 
is normalized, combining glycemia control and 
vitamin C, nitrotyrosine is also normalized. It 
has already been reported that Telmisartan 
reduces free radical production and oxidative 
stress (21-22). In this study, we show that 
Telmisartan influences the oxidative stress 
generation in diabetes. In the phase 2 of the 
study, as already reported for type 2 diabetic 
patients (23), the effect of the chronic treatment 
with an AT-1 blocker in decreasing 
nitrotyrosine plasma level is demonstrated, 
while the effect of Telmisartan on nitrotyrosine 
plasma levels in all the three protocols is 
equivalent to that of vitamin C. Interestingly, 
when vitamin C is added during the protocols 
in the patients already on Telmisartan 
treatment, it does not influence the results. 
These data, all together, suggest that 
Telmisartan reduces oxidative stress, achieving 
the same results of a well established 
antioxidant, such as vitamin C. This is 
particularly interesting, considering that 
hyperglycemia-induced PKC over-expression 
mediated the activation of the NADPH oxidase 
and may cause eNOS uncoupling (24), which 
can, in turn, favour peroxynitrite generation, 
which actually causes the increase in 
nitrotyrosine and is able to oxidize BH4, the 
eNOS cofactor, to the BH3 radical (25).  In this 
case, vitamin C acts as a BH3 radical scavenger 
rather than an antioxidant, which reacts with 
superoxide (26).Because Telmisartan prevents 
NADPH activation, this property may 
contribute to explain our results (27). 
 
Our data suggest that hyperglycemia 
convincingly  induces an endothelial 
dysfunction trough the generation of an 
oxidative stress, because the administration of 
vitamin C (in the protocol B) in presence of 
hyperglycemia restores endothelial function 
and reduces nitrotyrosine plasma level, and 
because the normalization of glycemia (in the 
protocol A) is accompanied by an improvement 
of both endothelial function and nitrotyrosine. 
Therefore, considering the whole results, it 
seems reasonable that Telmisartan improves 
endothelial function because reduces oxidative 
stress. 
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for insulin, more than for the reduction of 
hyperglycemia, in determining the 
improvement of endothelial dysfunction might 
be supposed. However, very recently, Ellger et 
al. have shown, in an animal model, that is the 
reduction of glucose toxicity, more than the 
action of insulin that improves endothelial 
function (28). 
 
As above reported, previous studies have 
shown that in type 1 diabetic patients even 
normalizing glycemia endothelial dysfunction 
still persists (8-9), suggesting that long lasting 
hyperglycemia can induce several permanent 
alterations in endothelial cells leading to a 
permanent endothelial dysfunction. Our data 
suggest that this permanent alteration induces 
the persistence of the endothelial dysfunction 
through the generation of oxidative stress, 
because by adding vitamin C or Telmisartan to 
the insulin the endothelial function is almost 
normalized. Interestingly, these in vivo data are 
consistent with in vitro and animal studies: in 
endothelial cells in culture and in the retina of 
diabetic rats an overproduction of free radicals 
persists even after the normalization of the 
glucose and is accompanied by a prolongation 
of the induction of PKC-β, NAD(P)H oxidase, 
Bax, collagen and fibronectin, in addition to 
nitrotyrosine (29), suggesting that oxidative 
stress may be involved in this effect. In the 
animals the evidences are more consistent. The 
effect of reinstitution of good glucose control 
on hyperglycaemia-induced increased oxidative 
stress and nitrative stress has been evaluated in 
the retina of rats maintained in poor glucose 
control before initiation of good control (29). In 
diabetic rats, 2 or 6 months of poor control 
(GHb >11.0%) was followed by 7 months of 
good control (GHb <5.5%). Reinstitution of 
good control after 2 months of poor control 
inhibited elevations in retinal lipid peroxides 
and NO levels by approximately 50%, but 
failed to have any beneficial effects on 
nitrotyrosine formation. However, reversal of 
hyperglycaemia after 6 months of poor control 
had no significant effect on retinal oxidative 
stress and NO levels. In the same rats, 
inducible nitric oxide synthase expression and 
nitrotyrosine levels remained elevated by >80% 
compared with normal rats or rats kept in good 
control for the duration (29). In a similar study, 
caspase-3 activity in diabetic rats kept in poor 
control for 13 months was 175% that in normal 
rats (30). Re-institution of good glycaemic 
control after two months of poor control 
partially normalized the hyperglycaemia-
induced activation of caspase-3 (to 140% of 
normal values) while re-institution of good 
control after six months of poor control had no 
significant effect on the activation of caspase-3. 
In the same study NF-kB activity was 2.5-fold 
higher in diabetic rats kept in poor control than 
in normal rats. Re-institution of good control 
after 2 months of poor control partially 
reversed this increase, but good control after 6 
months of poor control had no effect. Initiation 
of good control soon after induction of diabetes 
in rats prevented activation of retinal caspase-3 
and NF-kB (30). Similar results are available 
for the kidney. Diabetic rats were maintained in 
good glycaemic control (5% glycated 
hemoglobin, GHb) soon after or 6 months after 
induction of hyperglycaemia, and were 
sacrificed 13 months after induction of diabetes 
(31). For rats in which good control was 
initiated soon after induction of diabetes, 
oxidative stress [as measured by the levels of 
lipid peroxides (LPOs), 8-hydroxy-2'-
deoxyguanosine (8-OHdG), and reduced 
glutathione (GSH)] and NO in urine and renal 
cortex were not different from that observed in 
normal control rats, but when reinstitution of 
good control was delayed for 6 months after 
induction of diabetes, oxidative stress and NO 
remain elevated in both urine and renal cortex 
(31).  
These data suggests that hyperglycaemia-
induced oxidative stress and NO, as well as 
activation of apoptosis and of the NF-kB can be 
prevented if good glycaemic control is initiated 
very early, but are not easily reversed if poor is 
maintained for longer durations. Therefore, 
these findings suggest a persistence of the 
hyperglycaemia-induced damage in such 
organs even after its normalization. 
 
Because in vitro evidences show that almost 
the same pathways are activated by 
hyperglycemia in endothelial cells (32), it is 
reasonable that the cardiovascular system 
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kidney. 
 
The finding that only the simultaneous control 
of glycemia and oxidative stress can normalize 
endothelial function in type 1 diabetic patients 
is clearly relevant. This evidence seems to 
suggest the existence of   two different 
pathways working in the generation of 
endothelial dysfunction in type 1 diabetes: one 
directly related to hyperglycemia and one not. 
The explanation of this second pathway may 
be, at the moment, only speculative. It is well 
recognized that hyperglycemia, both chronic or 
acute, can induce an endothelial dysfunction 
through the generation of an oxidative stress, 
convincingly generated at the level of 
mitochondria (11,32). However, it is well 
recognized that chronic hyperglycemia induces 
the formation of the advanced end products 
(AGE) and chronic hyperglycemia is thought to 
alter mitochondrial function through glycation 
of mitochondrial proteins (33).   This premise 
is important because a recent study, for the first 
time, has described a direct relationship 
between the formation of intracellular AGEs on 
mitochondrial proteins, the decline in 
mitochondrial function and the excess 
formation of reactive species (34): 
mitochondrial respiratory chain proteins that 
underwent glycation were prone to produce 
more •O2
-, independently from the level of 
hyperglycemia. Therefore, a possible 
explanation for the previous evidences and of  
our data is that two pathways are 
simultaneously working: one due to the actual 
level of glycemia and another one to the long 
lasting damage induced in the endothelial cells 
by chronic hyperglycemia, possibly through 
non-enzymatic glycation of mitochondria. This 
hypothesis has recently been reviewed (35). 
It is also surprising that vitamin C or 
Telmisartan alone cannot normalize endothelial 
function if oxidative stress is the key 
convergent effectors of both hyperglycemia 
and of the long lasting damage (non-enzymatic 
glycation of mitochondria?). However, it may 
be hypothesized that when hyperglycemia is 
present it induces free radical generation which 
can be only partly counterbalanced by the 
antioxidant treatment: the persistence of 
increased levels of nitrotyrosine in the protocol 
B or after long-term Telmisartan treatment 
supports this hypothesis. Conversely, when 
hyperglycemia is normalized, the possible 
presence of a second pathway, still producing 
free radicals, also may explain the incomplete 
action of vitamin C or Telmisartan. 
 
In any case, although the molecular basis for 
our findings is not clear, we believe that the 
clinical impact of our finding is important. 
Particularly, the evidence that Telmisartan has 
the same beneficial effect of vitamin C in 
improving the long-lasting effect of 
hyperglycemia, in our opinion deserves 
attention. In fact, the effectiveness of a chronic 
long-term with vitamin C is still an open debate 
(36), while Telmisartan, as others AT-1 
receptor blockers, are already widely used for 
the prevention of diabetic complications, 
particularly nephropathy (37).  It seems 
reasonable to suggest that AT-1 receptor 
blocker is a much better kind of therapy as 
compared to vitamin C also because a recent 
study indicates that vitamin C intake increases 
mortality in postmenopausal women with 
diabetes type II (38). 
 
Moreover, the persistence of an endothelial 
dysfunction, which is a strong predictor of a 
cardiovascular event (4), even when glycemia 
is normalized, may contribute to explain the 
recent results from the EDIC/DCCT Study, 
showing, for the first time, the influence of the 
early glycemic control on the progression to 
macrovascular events (3). Of relevance, is also 
the evidence that in our study nitrotyosine is 
still elevated even in presence of near normal 
glycemia, since nitrotyrosine has also been 
shown to be an independent predictor of 
cardiovascular disease (39). Furthermore, our 
data seem to confirm that an early continuous 
aggressive treatment of glycemia is important 
to avoid future complications. Incidentally, in 
our opinion, the recent findings showing the 
existence of a continuum between the values of 
glycemia, endothelial dysfunction and the risk 
of a cardiovascular event, even in non diabetic 
patients, supports this concept (40-41). 
  7The use of AT-1 blockers for the prevention of 
cardiovascular complications, particularly in 
diabetes is still an open question (42). Our 
study showing, for the first time, that a 
normalization of both endothelial dysfunction 
and oxidative stress can be achieved in type 1 
diabetic patients combining the near 
normalization of glycemia and Telmisartan 
treatment, add a little piece in favor of the use 
of these compounds. Future long term 
controlled trials may help in understanding the 
possible clinical impact of this finding on the 
prognosis of cardiovascular disease in type 1 
diabetic patients. 
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